SCHEMBL5459377

SCHEMBL5459377

Cc1ccc(CNC(=O)Nc2sc3c(c2C(N)=O)CCOC3)cc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CFTR P13569 2/20 0.60
ANO1 Q5XXA6 2/20 0.52
FLT3 P36888 1/20 0.51
TP53 P04637 2/20 0.48
MAPT P10636 2/20 0.48
USP36 Q9P275 1/20 0.47
CNR2 P34972 5/20 0.47
PTGER4 P35408 2/20 0.46
PTPRC P08575 1/20 0.45
PTPN2 P17706 1/20 0.45
PTPN1 P18031 1/20 0.45
PTPRB P23467 1/20 0.45
PTPRE P23469 1/20 0.45
NPC1 O15118 2/20 0.44
MEN1 O00255 1/20 0.44
RAB9A P51151 1/20 0.44
EPHB4 P54760 1/20 0.44
KMT2A Q03164 1/20 0.44
CNR1 P21554 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459985 0.90 CFTR (0.57) CFTRANO1FLT3MAPTUSP36
SCHEMBL5458411 0.89 CFTR (0.55) CFTRFLT3MAPTUSP36CNR2
SCHEMBL5456065 0.88 CFTR (0.56) CFTRANO1FLT3MAPTUSP36
SCHEMBL5454158 0.86 FLT3 (0.68) CFTRFLT3TP53MAPTNPC1
SCHEMBL5449304 0.85 CFTR (0.65) CFTRANO1FLT3NPC1MEN1
SCHEMBL5458021 0.84 CFTR (0.58) CFTRANO1FLT3CNR2NPC1
SCHEMBL5456106 0.84 CFTR (0.58) CFTRANO1FLT3TP53MAPT
SCHEMBL5458457 0.82 FLT3 (0.52) CFTRFLT3TP53MAPTCNR2
SCHEMBL5450840 0.81 CFTR (0.54) CFTRANO1FLT3TP53MAPT
SCHEMBL5458242 0.80 CFTR (0.59) CFTRANO1MAPTNPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885ANO1 3245/4885FLT3 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.